However, substantial side effects linked to GAT1 inhibition, such as asthenia, dizziness, nervousness, and depression25–27, have limited the use of tiagabine, and interest in the non-GAT1 subtypes, especially BGT1, has therefore emerged18,19,28. Here, SLC6A1 is linked to asthenia.